Skip to main content

Table 5 Difference of ln-transformed PK variables between high-fat versus fasting condition (PP; n = 21) for Ciclosporin Pro and Sandimmun® Optoral

From: Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants

PK parameter

DCiclosporin Pro

Mean [SD]

DCiclosporin Pro

[95% CI]

Testing of H0*

t-value

p-value**

AUCSS, τ

−0.1252 [0.2008]

[−0.2166; − 0.0338]

−2.86

0.0097

CSS, max

−0.3916 [0.4371]

[− 0.5906; − 0.1927]

−4.11

0.0005

CSS, min

− 0.0690 [0.2094]

[− 0.1644; 0.0263]

−1.51

0.1465

PK parameter

DSandimmun Optoral

Mean [SD]

DSandimmun Optoral

[95% CI]

Testing of H0*

t-value

p-value**

AUCSS, τ

−0.1747 [0.1443]

[−0.2403; − 0.1090]

−5.55

<.0001

CSS, max

−0.5183 [0.3148]

[− 0.6616; − 0.3750]

−7.55

<.0001

CSS, min

− 0.0227 [0.1789]

[− 0.1041; 0.0588]

−0.58

0.5681

  1. * Testing of H0 (DCiclosporin Pro = 0) by means of the two-sided paired t-test
  2. ** lowest (two-sided) significance level, for which the null hypothesis could be rejected